Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
03/18/15 AW Withdrawal of amendment to a registration statement filed under the Securities Act HTML PDF 1
03/16/15 4 Statement of changes in beneficial ownership of securities HTML PDF 2
03/16/15 4 Statement of changes in beneficial ownership of securities HTML PDF 2
03/13/15 EFFECT Notice of Effectiveness HTML PDF 1
03/11/15 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 1
03/09/15 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 39
03/04/15 S-1/A General form of registration statement for all companies including face-amount certificate companies
Related Documents
EX-23.1
HTML PDF XBRL Viewer XLS XBRL Files 97
03/04/15 POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
Related Documents
EX-21.1
EX-23.1
HTML PDF XBRL Viewer XLS XBRL Files 111
03/03/15 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 2
03/03/15 S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Related Documents
EX-4.21
EX-5.1
EX-23.1
HTML PDF 46
RSS
  • << Previous
  • 1...
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • ...97
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Jun 11, 2026

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Read More...
Jun 1, 2026

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Read More...
May 11, 2026

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

Read More...

Promising Breast Cancer Vaccine

Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap